Bias amplification of unobserved confounding in pharmacoepidemiological studies using indication-based sampling.

We conclude that studies using indication-based sampling should have robust justification - and that it should by no means be considered unbiased to adopt such approaches. As such, we suggest that future observational studies stay wary of bias amplification when considering drug indications. This article is protected by copyright. All rights reserved.